{"classes":[{"categories":[{"measurements":[{"comment":"The median duration of response is not estimable if less than half of the participants had an event (progression or death).","groupId":"OG000","lowerLimit":"273","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Defined as the time from the earliest date of disease response (CR or PR) until earliest date of disease progression or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"INCAGN01876 in combination with pembrolizumab and epacadostat","id":"OG000","title":"INCAGN01876 + Pembrolizumab + Epacadostat"}],"paramType":"MEDIAN","populationDescription":"The FAS includes all participants enrolled in the study who received at least 1 dose of INCAGN01876, pembrolizumab, or epacadostat.","reportingStatus":"POSTED","timeFrame":"Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months","title":"Phase 1 & Phase 2: Duration of Response Based on RECIST v1.1 and mRECIST","type":"SECONDARY","unitOfMeasure":"days"}